Guard Therapeutics International AB (publ)

Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, develops novel therapies for diseases with high unmet medical need, primarily focusing on various forms of kidney disease in Sweden. The company’s pipeline products include RMC-035, an intact therapeutic A1M protein, that is in a Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in a preclinical trial to treat sepsis. It also develops GTZ peptides, a modified A1M-derived peptide which is in preclinical studies for the treatment of CKD and diabetes, heart failure, alport syndrome, sickle-cell nephropathy, and preeclampsia. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.